Trial Profile
A Phase 2, Multicenter, Open Label Study to Evaluate the Efficacy and Safety of OK-432 Immunotherapy in Individuals With Lymphatic Malformations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Picibanil (Primary)
- Indications Lymphatic disorders
- Focus Therapeutic Use
- 12 May 2022 According to a Protara Therapeutics media release, retrospective data from this study were presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2022.
- 12 May 2022 retrospective analysis results presented in a Protara Therapeutics media release.
- 04 Dec 2018 Status changed from active, no longer recruiting to completed.